Anti-LILRB1/CD85j/ILT2 Monoclonal Antibody for WB, FC, ELISA - Q8NHL6

Core Product Specifications and Parameters

Biological Background: LILRB1 Function and Localization

• LILRB1 (also known as ILT2, LIR1, MIR7, CD85J) is a member of the leukocyte immunoglobulin-like receptor subfamily B, containing Ig-like domains and cytoplasmic ITIM motifs that mediate inhibitory signaling.
• It functions as a receptor for a broad spectrum of classical and non-classical MHC class I molecules, including HLA-A, HLA-B, HLA-C, HLA-G, and HLA-F, and also recognizes the HCMV immunoevasin UL18. Related references: PMID:16455647, PMID:28636952
• Ligand engagement on NK cells and T cells inhibits cellular cytotoxicity and protects target cells from lysis; on B cells, it reprograms toward an immunosuppressive phenotype. Related references: PMID:9285411, PMID:9842885, PMID:24453251
• LILRB1 interacts with peptide-bound HLA-G, leading to the secretion of growth-promoting factors by decidual NK cells, contributing to maternal-fetal tolerance. Related references: PMID:16455647, PMID:19304799, PMID:29262349
• The receptor is predominantly expressed on the cell membrane, but a soluble secreted isoform exists; it is highly expressed in B cells, monocytes, various dendritic cell subsets, decidual macrophages, and decidual NK cells. Related references: PMID:20448110, PMID:24453251, PMID:9285411, PMID:9842885, PMID:19304799, PMID:29262349
• Post-translational modifications include phosphorylation of ITIM motifs (recruiting SHP-1 and SHP-2 phosphatases) and N-linked glycosylation; the protein features immunoglobulin domains, disulfide bonds, and alternative splicing.
• It plays a key role in immune evasion, both in viral infection (through UL18 mimicry) and in the tumor microenvironment, where HLA-G overexpression suppresses antitumor immunity.

Experimental Guidance and Technical Tips

• The immunogen corresponds to the recombinant human LILRB1 protein, likely targeting extracellular epitopes; consider this when designing blocking or competition assays.
• For Western blot (WB), note that the protein may migrate at multiple molecular weights (49 kDa, 70 kDa, 71 kDa) due to differential glycosylation or alternative splicing; include appropriate positive controls and adjust sample preparation to capture all forms.
• For flow cytometry (FC), use a live-cell surface staining protocol without permeabilization, given the receptor’s native cell membrane localization; titrate the antibody to minimize background on primary immune cells.
• ELISA applications may require optimization of coating and detection conditions; using a matched pair with a capture antibody can enhance sensitivity if developing a sandwich ELISA.
• Validate the antibody performance in your specific biological sample system (e.g., PBMCs, decidual tissues, tumor-infiltrating lymphocytes) and consider functional assays such as ligand-binding inhibition or ITIM phosphorylation readouts.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic. This LILRB1 monoclonal antibody exemplifies our capability to supply high-quality reagents for immune checkpoint and immuno-oncology research. Rely on CamelBio for validated antibody pairs, optimized monoclonal/polyclonal antibodies, bulk ancillary reagents, and sourcing of rare-target raw materials to accelerate your diagnostic development pipeline.